Display options
Cite
Timour Q, Aupetit JF, Loufoua-Moundanga J, et al. Ventricular and atrial electrophysiological effects of a IC antiarrhythmic drug, cibenzoline, in the innervated dog heart. Role of sodium and calcium channels. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(3):338-44doi: 10.1007/BF00168520.
Timour, Q., Aupetit, J. F., Loufoua-Moundanga, J., Bertrix, L., Freysz, M., & Faucon, G. (1989). Ventricular and atrial electrophysiological effects of a IC antiarrhythmic drug, cibenzoline, in the innervated dog heart. Role of sodium and calcium channels. Naunyn-Schmiedeberg's archives of pharmacology, 340(3), 338-44. https://doi.org/10.1007/BF00168520
Timour, Q, et al. "Ventricular and atrial electrophysiological effects of a IC antiarrhythmic drug, cibenzoline, in the innervated dog heart. Role of sodium and calcium channels." Naunyn-Schmiedeberg's archives of pharmacology vol. 340,3 (1989): 338-44. doi: https://doi.org/10.1007/BF00168520
Timour Q, Aupetit JF, Loufoua-Moundanga J, Bertrix L, Freysz M, Faucon G. Ventricular and atrial electrophysiological effects of a IC antiarrhythmic drug, cibenzoline, in the innervated dog heart. Role of sodium and calcium channels. Naunyn Schmiedebergs Arch Pharmacol. 1989 Sep;340(3):338-44. doi: 10.1007/BF00168520. PMID: 2554155.
Copy Download .nbib Format: NLM
Share it on

Naunyn Schmiedebergs Arch Pharmacol. 1989 Sep;340(3):338-44. doi: 10.1007/BF00168520.

Ventricular and atrial electrophysiological effects of a IC antiarrhythmic drug, cibenzoline, in the innervated dog heart. Role of sodium and calcium channels.

Naunyn-Schmiedeberg's archives of pharmacology

Q Timour, J F Aupetit, J Loufoua-Moundanga, L Bertrix, M Freysz, G Faucon

Affiliations

  1. Laboratoire de Pharmacologie Médicale, Lyon, France.

PMID: 2554155 DOI: 10.1007/BF00168520

Abstract

The effects of cibenzoline, rightly known as a sodium channel inhibitor (class IC antiarrhythmic drug), were investigated in anaesthetized, closed-chest dogs, on conduction in the contractile fibres, ventricular and atrial, the His-Purkinje system and the atrioventricular node. In ventricular muscle, conduction time was measured between base and apex by two endocavitary electrodes. The other conduction times were obtained from the recording of the His bundle potentials. In addition, effective refractory period was determined by the extrastimulus method in ventricular and atrial muscle and in the atrioventricular node, and sinus rate monitored in the intervals of pacing periods. In the absence of vagal tone, cibenzoline in 4 mg.kg-1 dose prolonged conduction times in the ventricular contractile tissue, His-Purkinje system and atrial contractile tissue to a large extent, but decreasingly from the former to the latter. This prolongation was antagonized by hypernatremia (174 mmol.l-1). In contrast, conduction time in the atrioventricular node, effective refractory periods and sinus rate were very little influenced. In the presence of vagal tone, the prolongation of conduction times in the ventricular contractile tissue. His-Purkinje system and atrial contractile tissue did not differ substantially from previously. It was the same for ventricular effective refractory period. But atrial effective refractory period was then considerably lengthened, while conduction time and effective refractory period in the atrioventricular node were greatly shortened and sinus rate notably accelerated.(ABSTRACT TRUNCATED AT 250 WORDS)

Similar articles

Show all 9 similar articles

References

  1. J Pharmacol. 1983 Jul-Sep;14(3):361-72 - PubMed
  2. Br J Pharmacol. 1982 Mar;75(3):469-78 - PubMed
  3. Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):196-201 - PubMed
  4. Prog Biophys Mol Biol. 1980;36(1):1-52 - PubMed
  5. Am Heart J. 1981 Nov;102(5):864-71 - PubMed
  6. J Cardiovasc Pharmacol. 1979 Jul-Aug;1(4):427-39 - PubMed
  7. Am Heart J. 1981 Oct;102(4):801-3 - PubMed
  8. J Pharmacol Exp Ther. 1977 Jun;201(3):669-77 - PubMed
  9. Circ Res. 1955 Jul;3(4):390-6 - PubMed
  10. Arch Int Pharmacodyn Ther. 1984 Jun;269(2):219-35 - PubMed
  11. Naunyn Schmiedebergs Arch Pharmacol. 1985 Apr;329(2):182-7 - PubMed
  12. Am Heart J. 1984 Jun;107(6):1161-8 - PubMed
  13. J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):6-13 - PubMed
  14. Arch Int Pharmacodyn Ther. 1984 Jun;269(2):201-18 - PubMed
  15. Int J Cardiol. 1987 Apr;15(1):65-76 - PubMed
  16. Circ Res. 1972 Feb;30(2):210-6 - PubMed
  17. Fed Proc. 1981 Jun;40(8):2226-32 - PubMed
  18. Am J Clin Pathol. 1972 Oct;58(4):376-82 - PubMed
  19. Arch Int Pharmacodyn Ther. 1983 Feb;261(2):238-48 - PubMed
  20. J Am Coll Cardiol. 1984 Mar;3(3):857-64 - PubMed
  21. Biochim Biophys Acta. 1977 Nov 14;472(3-4):373-98 - PubMed
  22. J Physiol. 1978 Jul;280:537-58 - PubMed
  23. Fundam Clin Pharmacol. 1989;3(3):281-94 - PubMed
  24. J Gen Physiol. 1969 Nov;54(5):607-35 - PubMed
  25. J Mol Cell Cardiol. 1984 Jan;16(1):65-77 - PubMed
  26. Naunyn Schmiedebergs Arch Pharmacol. 1983 Feb;322(1):59-64 - PubMed
  27. Annu Rev Physiol. 1984;46:473-84 - PubMed
  28. Cardiovasc Res. 1983 Dec;17(12):756-61 - PubMed
  29. Arch Int Pharmacodyn Ther. 1988 May-Jun;293:97-108 - PubMed
  30. Br J Pharmacol. 1978 Aug;63(4):587-91 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources